ReviewThe lancet. HIV2020
Epidemiology of haematological malignancies in people living with HIV.
Review in The lancet. HIV, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 93 citations in OpenAlex.
- Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.The Lancet. Global health · 2021Trial
- Characteristics of solid versus hematologic malignancies in people living with human immunodeficiency virus.BMC infectious diseases · 2026Article
- Clinical Characteristics and Prognostic Analysis of EBV-Positive HIV-Associated Diffuse Large B-Cell Lymphoma in China: A Retrospective Single-Center Study.Current oncology (Toronto, Ont.) · 2026Article
- Hodgkin and non-Hodgkin lymphomas in the post-antiretroviral therapy era according to HIV virological suppression.HIV medicine · 2026Observational
- Hemophagocytic lymphohistiocytosis in HIV-related lymphomas: a multicentre retrospective cohort study.Leukemia · 2026Article
- Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability.AIDS (London, England) · 2026Article
- Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus-Associated Disorders.Cancer reports (Hoboken, N.J.) · 2026Article
- Acute myeloid leukemia in HIV-positive patients: biological crossroads and therapeutic Hurdles.Clinical and experimental medicine · 2026Review
- Relapse of HIV-associated multicentric Castleman disease temporally associated with acute coronavirus disease 2019: a case report.BMC infectious diseases · 2026Article
- Incidence rates of non-Hodgkin lymphoma subtypes among Black Africans with and without HIV in South Africa: a national registry-based study.The Lancet regional health. Africa · 2026Article
- Integrating Flow Cytometry in the Diagnostic Work of HIV-Associated Hodgkin's Lymphomas.Journal of cellular and molecular medicine · 2026Review
- Article
- Article
- Article
- Caregiver burden and malnutrition in patients with HIV-associated lymphoma: indirect pathways via symptom distress and family closeness, and a test of resilience as a mediator.Frontiers in nutrition · 2026Article
- Light Chain Deposition Disease and Light Chain Cast Nephropathy in a Patient With Multiple Myeloma and HIV Infection: A Case Report.Case reports in nephrology · 2026Article
- Learning from nature: HIV elite controllers as blueprints for a functional cure.Virology journal · 2025Review
- Hodgkin lymphoma treatment patterns and outcome disparities in low- and middle-income countries.Blood global hematology · 2025Article
- Immunogenomic profiles of HIV-associated classic Hodgkin lymphoma from Malawi.Blood global hematology · 2025Article
- Immunosenescence phenotypes and prognostic significance of CD8 + CD28- T cells in AIDS-related non-Hodgkin lymphoma.Annals of medicine · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
People living with HIV or AIDS are at increased risk of Hodgkin and non-Hodgkin lymphoma compared with HIV-negative individuals. Data on the risk of multiple myeloma or leukaemia are inconsistent and of low quality but the risk does not seem to be increased. Specific haematological malignancies occur in different contexts of age, CD4 cell count, HIV control, viral co-infections, or chronic inflammation, and the expansion of combination antiretroviral therapy has led to varied demographic and epidemiological shifts among people with HIV. Increased use of combination antiretroviral therapy has substantially reduced the risks of diffuse large B-cell lymphoma, Burkitt lymphoma, and primary CNS lymphoma, and to a lesser extent, Hodgkin lymphoma. There is no effect of combination antiretroviral therapy use on multiple myeloma or leukaemia. Although many cases of HIV are in low-income and middle-income countries, high-quality epidemiological data for haematological malignancies from these regions are scarce. Closing this gap is an essential first step in decreasing mortality from HIV-associated haematological malignancies worldwide. Finally, although multicentric Castleman disease is not a neoplastic condition, it is an emerging precursor to neoplastic high-grade B-cell lymphoproliferation among people with HIV, especially for individuals on long-term combination antiretroviral therapy with well controlled HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.